TY - JOUR
T1 - Emerging Treatments for Disorders of Consciousness in Paediatric Age
AU - Irzan, Hassna
AU - Pozzi, Marco
AU - Chikhladze, Nino
AU - Cebanu, Serghei
AU - Tadevosyan, Artashes
AU - Calcii, Cornelia
AU - Tsiskaridze, Alexander
AU - Melbourne, Andrew
AU - Strazzer, Sandra
AU - Modat, Marc
AU - Molteni, Erika
N1 - Funding Information:
Author Contributions: All the authors contributed to this manuscript. H.I. and E.M. drafted the manuscript. E.M. and S.S. conceptualized Section 2. M.P. conceptualized Section 3. E.M., A.M. and H.I. conceptualized Section 4. E.M. conceptualized Section 5. N.C., S.C., A.T. (Artashes Tadevosyan), C.C., A.T. (Alexander Tsiskaridze) and S.S. conceptualized Section 6. All authors have read and agreed to the published version of the manuscript. Funding: Hassna Irzan is supported by the EPSRC-funded UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1), the Department of Health NIHR-funded Biomedical Research Centre at University College London Hospitals and Medical Research Council (MR/N024869/1). Marco Pozzi and Sandra Strazzer are supported by the Italian Ministry of Health (Ricerca Corrente). Andrew Melbourne is supported by the Wellcome trust (210182/Z/18/Z, 101957/Z/13/Z, 203148/Z/16/Z) and the EPSRC (NS/A000027/1). Marc Modat is supported by the UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare. Erika Molteni is funded by an MRC Skills Development Fellowship Scheme at King’s College London. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Conflicts of Interest: The authors have no conflicts of interest relevant to this article to disclose. The funders did not participate in the work.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/2
Y1 - 2022/2
N2 - The number of paediatric patients living with a prolonged Disorder of Consciousness (DoC) is growing in high-income countries, thanks to substantial improvement in intensive care. Life expectancy is extending due to the clinical and nursing management achievements of chronic phase needs, including infections. However, long-known pharmacological therapies such as amantadine and zolpidem, as well as novel instrumental approaches using direct current stimulation and, more recently, stem cell transplantation, are applied in the absence of large paediatric clinical trials and rigorous age-balanced and dose-escalated validations. With evidence building up mainly through case reports and observational studies, there is a need for well-designed paediatric clinical trials and specific research on 0-4-year-old children. At such an early age, assessing residual and recovered abilities is most challenging due to the early developmental stage, incompletely learnt motor and cognitive skills, and unreliable communication; treatment options are also less explored in early age. In middle-income countries, the lack of rehabilitation services and professionals focusing on paediatric age hampers the overall good assistance provision. Young and fast-evolving health insurance systems prevent universal access to chronic care in some countries. In low-income countries, rescue networks are often inadequate, and there is a lack of specialised and intensive care, difficulty in providing specific pharmaceuticals, and lower compliance to intensive care hygiene standards. Despite this, paediatric cases with DoC are reported, albeit in fewer numbers than in countries with better-resourced healthcare systems. For patients with a poor prospect of recovery, withdrawal of care is inhomogeneous across countries and still heavily conditioned by treatment costs as well as ethical and cultural factors, rather than reliant on protocols for assessment and standardised treatments. In summary, there is a strong call for multicentric, international, and global health initiatives on DoC to devote resources to the paediatric age, as there is now scope for funders to invest in themes specific to DoC affecting the early years of the life course.
AB - The number of paediatric patients living with a prolonged Disorder of Consciousness (DoC) is growing in high-income countries, thanks to substantial improvement in intensive care. Life expectancy is extending due to the clinical and nursing management achievements of chronic phase needs, including infections. However, long-known pharmacological therapies such as amantadine and zolpidem, as well as novel instrumental approaches using direct current stimulation and, more recently, stem cell transplantation, are applied in the absence of large paediatric clinical trials and rigorous age-balanced and dose-escalated validations. With evidence building up mainly through case reports and observational studies, there is a need for well-designed paediatric clinical trials and specific research on 0-4-year-old children. At such an early age, assessing residual and recovered abilities is most challenging due to the early developmental stage, incompletely learnt motor and cognitive skills, and unreliable communication; treatment options are also less explored in early age. In middle-income countries, the lack of rehabilitation services and professionals focusing on paediatric age hampers the overall good assistance provision. Young and fast-evolving health insurance systems prevent universal access to chronic care in some countries. In low-income countries, rescue networks are often inadequate, and there is a lack of specialised and intensive care, difficulty in providing specific pharmaceuticals, and lower compliance to intensive care hygiene standards. Despite this, paediatric cases with DoC are reported, albeit in fewer numbers than in countries with better-resourced healthcare systems. For patients with a poor prospect of recovery, withdrawal of care is inhomogeneous across countries and still heavily conditioned by treatment costs as well as ethical and cultural factors, rather than reliant on protocols for assessment and standardised treatments. In summary, there is a strong call for multicentric, international, and global health initiatives on DoC to devote resources to the paediatric age, as there is now scope for funders to invest in themes specific to DoC affecting the early years of the life course.
KW - Paediatric Disorder of Consciousness
KW - treatment of Disorder of Consciousness
KW - pharmacology of paediatric brain injury
KW - rehabilitation of paediatric brain injury
KW - children’s brain injury global health
UR - http://www.scopus.com/inward/record.url?scp=85124974549&partnerID=8YFLogxK
U2 - 10.3390/brainsci12020198
DO - 10.3390/brainsci12020198
M3 - Article
C2 - 35203961
SN - 2076-3425
VL - 12
SP - e198
JO - Brain Sciences
JF - Brain Sciences
IS - 2
M1 - 198
ER -